ACRS Quote, Financials, Valuation and Earnings

Oramed Pharmaceuticals, Inc. has a net margin of -442.98% compared to Aclaris Therapeutics, Inc.'s net margin of -382.1%. Aclaris Therapeutics, Inc.'s return on equity of -103.93% beat Oramed Pharmaceuticals, Inc.'s return on equity of 27.49%.

Aclaris Therapeutics, Inc. has a consensus price target of $8.00, signalling upside risk potential of 152.37%. On the other hand Oramed Pharmaceuticals, Inc. has an analysts' consensus of $3.25 which suggests that it could fall by -1.52%. Given that Aclaris Therapeutics, Inc. has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe Aclaris Therapeutics, Inc. is more attractive than Oramed Pharmaceuticals, Inc..

Aclaris Therapeutics, Inc. has a beta of 0.860, which suggesting that the stock is 13.979% less volatile than S&P 500. In comparison Oramed Pharmaceuticals, Inc. has a beta of 1.342, suggesting its more volatile than the S&P 500 by 34.249%.

Aclaris Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oramed Pharmaceuticals, Inc. offers a yield of 7.58% to investors and pays a quarterly dividend of $0.25 per share. Aclaris Therapeutics, Inc. pays -- of its earnings as a dividend. Oramed Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Aclaris Therapeutics, Inc. quarterly revenues are $3.3M, which are larger than Oramed Pharmaceuticals, Inc. quarterly revenues of --. Aclaris Therapeutics, Inc.'s net income of -$14.6M is lower than Oramed Pharmaceuticals, Inc.'s net income of $48.4M. Notably, Aclaris Therapeutics, Inc.'s price-to-earnings ratio is -- while Oramed Pharmaceuticals, Inc.'s PE ratio is 3.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aclaris Therapeutics, Inc. is 23.30x versus 68.69x for Oramed Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Puma Biotechnology, Inc. has a net margin of -442.98% compared to Aclaris Therapeutics, Inc.'s net margin of 16.24%. Aclaris Therapeutics, Inc.'s return on equity of -103.93% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.

Aclaris Therapeutics, Inc. has a consensus price target of $8.00, signalling upside risk potential of 152.37%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $5.00 which suggests that it could fall by -25.15%. Given that Aclaris Therapeutics, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Aclaris Therapeutics, Inc. is more attractive than Puma Biotechnology, Inc..

Aclaris Therapeutics, Inc. has a beta of 0.860, which suggesting that the stock is 13.979% less volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.221, suggesting its more volatile than the S&P 500 by 22.056%.

Aclaris Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aclaris Therapeutics, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.

Aclaris Therapeutics, Inc. quarterly revenues are $3.3M, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Aclaris Therapeutics, Inc.'s net income of -$14.6M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Aclaris Therapeutics, Inc.'s price-to-earnings ratio is -- while Puma Biotechnology, Inc.'s PE ratio is 9.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aclaris Therapeutics, Inc. is 23.30x versus 1.58x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

PMV Pharmaceuticals, Inc. has a net margin of -442.98% compared to Aclaris Therapeutics, Inc.'s net margin of --. Aclaris Therapeutics, Inc.'s return on equity of -103.93% beat PMV Pharmaceuticals, Inc.'s return on equity of -51.97%.

Aclaris Therapeutics, Inc. has a consensus price target of $8.00, signalling upside risk potential of 152.37%. On the other hand PMV Pharmaceuticals, Inc. has an analysts' consensus of $7.60 which suggests that it could grow by 610.28%. Given that PMV Pharmaceuticals, Inc. has higher upside potential than Aclaris Therapeutics, Inc., analysts believe PMV Pharmaceuticals, Inc. is more attractive than Aclaris Therapeutics, Inc..

Aclaris Therapeutics, Inc. has a beta of 0.860, which suggesting that the stock is 13.979% less volatile than S&P 500. In comparison PMV Pharmaceuticals, Inc. has a beta of 1.396, suggesting its more volatile than the S&P 500 by 39.573%.

Aclaris Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PMV Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aclaris Therapeutics, Inc. pays -- of its earnings as a dividend. PMV Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Aclaris Therapeutics, Inc. quarterly revenues are $3.3M, which are larger than PMV Pharmaceuticals, Inc. quarterly revenues of --. Aclaris Therapeutics, Inc.'s net income of -$14.6M is higher than PMV Pharmaceuticals, Inc.'s net income of -$21.1M. Notably, Aclaris Therapeutics, Inc.'s price-to-earnings ratio is -- while PMV Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aclaris Therapeutics, Inc. is 23.30x versus -- for PMV Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Instil Bio, Inc. has a net margin of -442.98% compared to Aclaris Therapeutics, Inc.'s net margin of --. Aclaris Therapeutics, Inc.'s return on equity of -103.93% beat Instil Bio, Inc.'s return on equity of -50.54%.

Aclaris Therapeutics, Inc. has a consensus price target of $8.00, signalling upside risk potential of 152.37%. On the other hand Instil Bio, Inc. has an analysts' consensus of $29.00 which suggests that it could grow by 226.58%. Given that Instil Bio, Inc. has higher upside potential than Aclaris Therapeutics, Inc., analysts believe Instil Bio, Inc. is more attractive than Aclaris Therapeutics, Inc..

Aclaris Therapeutics, Inc. has a beta of 0.860, which suggesting that the stock is 13.979% less volatile than S&P 500. In comparison Instil Bio, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Aclaris Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Instil Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aclaris Therapeutics, Inc. pays -- of its earnings as a dividend. Instil Bio, Inc. pays out -- of its earnings as a dividend.

Aclaris Therapeutics, Inc. quarterly revenues are $3.3M, which are larger than Instil Bio, Inc. quarterly revenues of --. Aclaris Therapeutics, Inc.'s net income of -$14.6M is lower than Instil Bio, Inc.'s net income of -$13.6M. Notably, Aclaris Therapeutics, Inc.'s price-to-earnings ratio is -- while Instil Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aclaris Therapeutics, Inc. is 23.30x versus -- for Instil Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.